Alternatives to Johnson & Johnson — Changing health for humanity
People searching for Johnson & Johnson alternatives often need comparable scale in pharmaceutical development and medical device innovation without relying on a single legacy conglomerate. They compare global R&D pipelines, regulatory reach, and therapy areas such as oncology or orthopaedics when evaluating options for treatment portfolios, hospital procurement, or investment theses. Decision makers look at how competitors handle precision medicine, digital surgery platforms, and post-pandemic supply resilience. Queries frequently target companies with similar breadth in immunology or cardiovascular devices yet potentially faster decision cycles, different pricing structures for hospital systems, or stronger focus on niche indications. Understanding these trade-offs helps procurement teams, clinicians, and analysts select partners that match specific therapeutic gaps or regional access requirements.
COMPASS PathwaysCOMPASS Pathways develops psilocybin-based therapies for treatment-resistant depression with a focus on large Phase 3 trials and therapist-supported sessions. Its longer-duration psychedelic experience contrasts with Gilgamesh's short-acting 5-HT2AR agonist designed for a 2-hour window and potential scalability advantages post-AbbVie acquisition.
Gilgamesh PharmaceuticalsCOMPASS Pathways develops psilocybin-based therapies for treatment-resistant depression with a focus on large Phase 3 trials and therapist-supported sessions. Its longer-duration psychedelic experience contrasts with Gilgamesh's short-acting 5-HT2AR agonist designed for a 2-hour window and potential scalability advantages post-AbbVie acquisition.
ATAI Life SciencesATAI invests in and develops multiple mental health compounds including ketamine derivatives and ibogaine analogs. While broader in scope than Gilgamesh, ATAI previously acquired Gilgamesh founders' earlier companies, creating direct lineage overlap in psychedelic and ibogaine chemistry.
MindMedMindMed advances MM-120, a lysergide d-tartrate for anxiety disorders, and other psychedelic-inspired candidates. Its focus on regulated psychedelic sessions differs from Gilgamesh's emphasis on non-hallucinogenic neuroplastogens and oral NMDAR antagonists suitable for at-home use.
CybinCybin develops deuterated tryptamine analogs for depression and anxiety with improved pharmacokinetics. Its shorter-acting candidates share some mechanistic overlap with Gilgamesh's Bretisilocin but lack the same level of big-pharma acquisition validation to date.
Delix specializes in non-hallucinogenic psychoplastogens targeting structural brain plasticity. Its approach closely mirrors Gilgamesh's AbbVie-partnered neuroplastogen program, though Delix remains independent without equivalent late-stage partnership announcements.
Seelos TherapeuticsSeelos focuses on CNS candidates including SLS-002, an intranasal racemic ketamine for depression and suicidality. Its acute-use formulation differs from Gilgamesh's oral daily-potential NMDAR antagonist aimed at broader outpatient access.
Beckley PsytechBeckley Psytech develops synthetic 5-MeO-DMT and other short-acting psychedelics for depression. Its emphasis on rapid-onset, shorter-duration compounds parallels Gilgamesh's 5-HT2AR strategy but without the same disclosed big-pharma exit.
Small Pharma advances SPL026, a DMT-based short-acting psychedelic for depression. Its pharmacokinetic profile resembles Gilgamesh's Bretisilocin yet remains pre-partnership compared to the AbbVie-validated asset.
Lundbeck develops established psychiatric medications and has explored novel mechanisms for depression. As a large pharma, it offers approved products and global reach unlike Gilgamesh's early-clinical NCE pipeline focused on plasticity mechanisms.